Literature DB >> 32608106

White-coat and masked hypertension diagnoses in chronic kidney disease patients.

Henrique Pereira1, Alessandra Bonilha1, Pasqual Barretti1, Roberto Silva1, Vanessa Burgugi1, Vanessa Dos Santos1, Luis Cuadrado1.   

Abstract

The purpose of this study was to analyze which 24-hour ambulatory blood pressure measurement (ABPM) parameters should be used on masked hypertension (MH) and white-coat hypertension (WCH) diagnoses in chronic kidney disease (CKD) patients. Non-dialysis CKD patients underwent 24-hour ABPM examination between 01/27/2004 and 02/16/2012. They were followed from the 24-hour ABPM to January/2014 in an observational study. The WCH definitions tested were as follows: (a) office blood pressure (BP) ≥ 140/90 mm Hg and daytime ABPM BP ≤ 135/85 mm Hg (old criterion); and (b) office BP ≥ 140/90 mm Hg and 24-hour ABPM BP ≤ 130/80 mm Hg, daytime ABPM BP ≤ 135/85 mm Hg, and nighttime ABPM BP ≤ 120/70 mm Hg (new criterion). The MH definitions tested were as follows: (a) office BP < 140/90 mm Hg and daytime ABPM BP > 135/85 mm Hg (old criterion); and (b) office BP < 140/90 mm Hg and 24-hour ABPM BP > 130/80 mm Hg or daytime ABPM BP > 135/85 mm Hg or nighttime ABPM BP > 120/70 mm Hg (new criterion). The two definitions' predictive capacity was compared, regarding both WCH and MH. Cardiovascular mortality was the primary and all-cause mortality was the secondary outcome. Cox regression was adjusted to the variables: glomerular filtration rate, age, diabetes mellitus, and active smoking. There were 367 patients studied. The old criterion (exclusive mean daytime ABPM BP) was the only to distinguish sustained hypertension from WCH (adjusted HR: 3.730; 95% CI: 1.068-13.029; P = .039), regarding all-cause mortality. Additionally, the old criterion was the only one to distinguish normotension and MH, regarding cardiovascular mortality (adjusted HR: 7.641; 95% CI: 1.277-45.738; P = .026). Therefore, WCH and MH definitions based exclusively on daytime ABPM BP values (old criterion) were able to better distinguish mortality in this studied CKD cohort.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  ambulatory blood pressure measurement; chronic kidney disease; masked hypertension; white-coat hypertension

Mesh:

Year:  2020        PMID: 32608106      PMCID: PMC8029747          DOI: 10.1111/jch.13924

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  22 in total

1.  Masked hypertension.

Authors:  Thomas G Pickering; Karina Davidson; William Gerin; Joseph E Schwartz
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

2.  [V Guidelines for ambulatory blood pressure monitoring (ABPM) and III Guidelines for home blood pressure monitoring (HBPM)].

Authors: 
Journal:  Arq Bras Cardiol       Date:  2011-09       Impact factor: 2.000

3.  Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease.

Authors:  Roberto Minutolo; Rajiv Agarwal; Silvio Borrelli; Paolo Chiodini; Vincenzo Bellizzi; Felice Nappi; Bruno Cianciaruso; Pasquale Zamboli; Giuseppe Conte; Francis B Gabbai; Luca De Nicola
Journal:  Arch Intern Med       Date:  2011-06-27

4.  Prevalence and clinical characteristics of white-coat hypertension based on different definition criteria in untreated and treated patients.

Authors:  Alejandro de la Sierra; Ernest Vinyoles; José R Banegas; Julián Segura; Manuel Gorostidi; Juan J de la Cruz; Luis M Ruilope
Journal:  J Hypertens       Date:  2017-12       Impact factor: 4.844

Review 5.  Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension.

Authors:  George C Roush; Robert H Fagard; Gil F Salles; Sante D Pierdomenico; Gianpaolo Reboldi; Paolo Verdecchia; Kazuo Eguchi; Kazuomi Kario; Satoshi Hoshide; Jorge Polonia; Alejandro de la Sierra; Ramon C Hermida; Eamon Dolan; Hernan Zamalloa
Journal:  J Hypertens       Date:  2014-12       Impact factor: 4.844

6.  Relationship between ambulatory BP and clinical outcomes in patients with hypertensive CKD.

Authors:  Francis B Gabbai; Mahboob Rahman; Bo Hu; Lawrence J Appel; Jeanne Charleston; Gabriel Contreras; Marquetta L Faulkner; Leena Hiremath; Kenneth A Jamerson; Janice P Lea; Michael S Lipkowitz; Velvie A Pogue; Stephen G Rostand; Miroslaw J Smogorzewski; Jackson T Wright; Tom Greene; Jennifer Gassman; Xuelei Wang; Robert A Phillips
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-30       Impact factor: 8.237

7.  Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality.

Authors:  José R Banegas; Luis M Ruilope; Alejandro de la Sierra; Ernest Vinyoles; Manuel Gorostidi; Juan J de la Cruz; Gema Ruiz-Hurtado; Julián Segura; Fernando Rodríguez-Artalejo; Bryan Williams
Journal:  N Engl J Med       Date:  2018-04-19       Impact factor: 91.245

Review 8.  Ambulatory blood pressure in chronic kidney disease.

Authors:  Debbie L Cohen; Yonghong Huan; Raymond R Townsend
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

9.  White-coat and masked hypertension diagnoses in chronic kidney disease patients.

Authors:  Henrique Pereira; Alessandra Bonilha; Pasqual Barretti; Roberto Silva; Vanessa Burgugi; Vanessa Dos Santos; Luis Cuadrado
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-07-01       Impact factor: 3.738

10.  Reversed dipper blood-pressure pattern is closely related to severe renal and cardiovascular damage in patients with chronic kidney disease.

Authors:  Cheng Wang; Jun Zhang; Xun Liu; Cuicui Li; Zengchun Ye; Hui Peng; Zhujiang Chen; Tanqi Lou
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240

View more
  1 in total

1.  White-coat and masked hypertension diagnoses in chronic kidney disease patients.

Authors:  Henrique Pereira; Alessandra Bonilha; Pasqual Barretti; Roberto Silva; Vanessa Burgugi; Vanessa Dos Santos; Luis Cuadrado
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-07-01       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.